CA2110553A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
CA2110553A1
CA2110553A1 CA002110553A CA2110553A CA2110553A1 CA 2110553 A1 CA2110553 A1 CA 2110553A1 CA 002110553 A CA002110553 A CA 002110553A CA 2110553 A CA2110553 A CA 2110553A CA 2110553 A1 CA2110553 A1 CA 2110553A1
Authority
CA
Canada
Prior art keywords
compound
formula
trans
cis
choh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002110553A
Other languages
English (en)
French (fr)
Inventor
Michael M. Dreyfuss
Albert Leutwiler
Andrew R. Mackenzie
Jorg Schnyder
Rene P. Traber
Henri Mattes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2110553A1 publication Critical patent/CA2110553A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungi isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/08—Oxygen as only ring hetero atoms containing a hetero ring of at least seven ring members, e.g. zearalenone, macrolide aglycons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
CA002110553A 1992-12-04 1993-12-02 Organic compounds Abandoned CA2110553A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929225396A GB9225396D0 (en) 1992-12-04 1992-12-04 Improvements in or relating to organic compounds
GB9225396.2 1992-12-04

Publications (1)

Publication Number Publication Date
CA2110553A1 true CA2110553A1 (en) 1994-06-05

Family

ID=10726140

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002110553A Abandoned CA2110553A1 (en) 1992-12-04 1993-12-02 Organic compounds

Country Status (18)

Country Link
EP (1) EP0606044A1 (enExample)
JP (1) JPH06228122A (enExample)
KR (1) KR940014377A (enExample)
CN (1) CN1095417A (enExample)
AU (1) AU5211293A (enExample)
CA (1) CA2110553A1 (enExample)
CZ (1) CZ261493A3 (enExample)
FI (1) FI935409L (enExample)
GB (1) GB9225396D0 (enExample)
HU (1) HUT65910A (enExample)
IL (1) IL107838A0 (enExample)
MX (1) MX9307608A (enExample)
NO (1) NO934372L (enExample)
NZ (1) NZ250344A (enExample)
PL (1) PL301281A1 (enExample)
SK (1) SK135493A3 (enExample)
TW (1) TW258736B (enExample)
ZA (1) ZA939088B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228328C2 (de) * 1992-08-26 1999-02-11 Agie Sa Maschine und Verfahren zum funkenerosiven Drahtschneiden mit einer im Querschnitt verformten Drahtelektrode
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5731343A (en) * 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
ES2149468T3 (es) * 1995-04-26 2000-11-01 Kyowa Hakko Kogyo Kk Derivados de radicicol.
AU779438B2 (en) * 1998-12-24 2005-01-27 Novation Pharmaceuticals Inc. Compounds which affect mRNA stability and uses therefor
ATE328888T1 (de) 2000-08-25 2006-06-15 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
JP2004292314A (ja) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
JP2004292315A (ja) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd Ｔａｋ１阻害剤
GB0112522D0 (en) * 2001-05-23 2001-07-11 Ici Plc Catalytic process
CA2478065C (en) * 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
US7915306B2 (en) 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
RU2312863C2 (ru) * 2002-04-17 2007-12-20 Тайсо Фармасьютикал Ко., Лтд. Тоник для роста волос
US20060079494A1 (en) * 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
US7601852B2 (en) 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
CN105748465A (zh) 2007-07-25 2016-07-13 卫材R&D管理株式会社 用于治疗癌症的多激酶抑制剂
EP2453234B1 (en) 2007-10-29 2014-01-15 Eisai R&D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
MX2010005999A (es) 2007-12-07 2010-06-23 Eisai R&D Man Co Ltd Intermediarios en la sintesis de analogos de macrolidos de zearalenona.
AU2009303389B2 (en) 2008-10-17 2014-10-16 Wisconsin Alumni Research Foundation Method of making biologically active alpha-beta peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) * 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making

Also Published As

Publication number Publication date
NO934372D0 (no) 1993-12-02
SK135493A3 (en) 1994-08-10
FI935409A7 (fi) 1994-06-05
FI935409A0 (fi) 1993-12-02
MX9307608A (es) 1995-01-31
IL107838A0 (en) 1994-04-12
FI935409L (fi) 1994-06-05
NO934372L (no) 1994-06-06
PL301281A1 (en) 1994-06-13
JPH06228122A (ja) 1994-08-16
CZ261493A3 (en) 1994-07-13
HUT65910A (en) 1994-07-28
KR940014377A (ko) 1994-07-18
ZA939088B (en) 1995-06-05
HU9303444D0 (en) 1994-04-28
NZ250344A (en) 1995-10-26
CN1095417A (zh) 1994-11-23
AU5211293A (en) 1994-06-16
EP0606044A1 (en) 1994-07-13
TW258736B (enExample) 1995-10-01
GB9225396D0 (en) 1993-01-27

Similar Documents

Publication Publication Date Title
EP0606044A1 (en) Lactones compounds useful as pharmaceuticals
CA1046439A (en) Physiologically active substances from penicillium citrinum
DK149095B (da) Fremgangsmaade til fremstilling af en cholesterolsynteseinhiberende forbindelse kaldet monacolin k
BG100699A (bg) Карбоциклични съединения
AU640756B2 (en) 2,8-dioxabicyclo(3,2,1)octane derivatives,their production from cultures of MF 5447 and MF 5466 and their use as anti hyper cholesterolemics
EP0926242A1 (en) Gliotoxin derivatives and anticancer agent comprising the same
US5132320A (en) Squalene synthetase inhibitors
KR0135600B1 (ko) 항암 항생물질 mi43-37f11, 그 제조방법 및 그 용도
DK151273B (da) Fremgangsmaade til fremstilling af cholesterolbiosynteseinhibitoren mb- 530a.
US4945108A (en) Angucyclinones from streptomycetes, a process for the preparation thereof, and the use thereof
US5399587A (en) Biologically active compounds
US5712306A (en) Physiologically active substances PF1092A, PF1092B and PF1092C, and contraceptives and anticancer drugs containing the same as active ingredients
EP0458970A1 (en) Benzofuran derivative, process for preparing the same, and pharmaceutical comprising the same as active ingredient
US6518316B1 (en) Cytokine production and tyrosine kinase inhibitors
US3701787A (en) Preparation of 5,6-dihydro-5-hydroxy-6-propenyl-2-pyrone by fermentation and derivatives thereof
US4780311A (en) Antihypercholesterolemic tri-yne carbonates
EP0395418B1 (en) A phospholipase A2 inhibitor, method for producing it and pharmaceutical or veterinary formulations comprising said inhibitor
KR100322240B1 (ko) 페니실리움 속(Ｐｅｎｉｃｉｌｌｉｕｍ ｓｐ.)Ｆ70614(ＫＣＴＣ 8918Ｐ)와 α-글루코시다제 저해제
US5248790A (en) Aminoalkylphosphonic acid esters of natural 4-methoxy-5-methyl-pyran-3-ol and derivatives thereof
US5441987A (en) Antifungal agent
JP3641013B2 (ja) 新規な細胞接着阻害剤マクロスフェライドａ及びｂ並びにそれらの製造法
WO1991008222A1 (en) Physiologically active substance be-16627
KR100427411B1 (ko) 아스퍼질러스 속 Ｆ７０６０９（ＫＣＴＣ１８０５５Ｐ）와 β－글루코시다제 저해제
WO2001046451A1 (en) Migrastatin, process for producing the same and medicinal compositions
KR0176414B1 (ko) 신규 아실-코에이:콜레스테롤 아실전이효소 활성 저해물질 및 이의 제조방법

Legal Events

Date Code Title Description
FZDE Discontinued